Retatrutide

A GLP-1/GIP/GCG receptor agonist for weight loss and metabolic health.

About Retatrutide

Retatrutide is a cutting-edge investigational drug designed to address obesity and type 2 diabetes through a triple hormone approach. Unlike single-pathway treatments, Retatrutide activates three key receptors in the body:

GLP-1 (Glucagon-Like Peptide-1)** – reduces appetite and improves insulin response
GIP (Glucose-Dependent Insulinotropic Polypeptide)** – supports insulin secretion and metabolic balance
Glucagon receptor – boosts energy expenditure and fat burning

This combination helps regulate hunger, stabilize blood sugar, and accelerate weight loss. By mimicking the body’s natural hormonal signals, Retatrutide provides a more comprehensive metabolic effect compared to traditional GLP-1-only drugs.

Early clinical studies show that Retatrutide may lead to **significant weight loss** and improved metabolic health, making it a promising future treatment for obesity-related conditions.

Benefits

Research + Clinical Study Snippets

Over 24% weight reduction in clinical trial participants

Participants in phase 2 trials lost more than 24% of their body weight over 48 weeks — a record-high response in obesity treatment trials.

Significant reduction in HbA1c in T2D patients

Retatrutide showed strong glucose-lowering effects, with major reductions in HbA1c in patients with type 2 diabetes, alongside weight loss.

Triple hormone mechanism improves metabolic regulation

Activating GLP-1, GIP, and glucagon receptors leads to appetite suppression, enhanced insulin sensitivity, and increased fat metabolism.

Safe and well-tolerated in trials

Most side effects were mild to moderate (like nausea), and similar to those seen with other incretin-based therapies.

Read the full clinical trial on PubMed

Retatrutide Kits / Vials

Retatrutide is a novel multi-receptor agonist that targets the GLP-1, GIP, and glucagon receptors to deliver powerful benefits in weight reduction, blood sugar control, and overall metabolic regulation. By combining these three hormonal pathways, Retatrutide offers a more comprehensive approach than existing single-pathway therapies.